MedTrace Logo

NR in Chemo-induced Peripheral Neuropathy

NCT03642990 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-04-12

Study results available
· View outcomes & findings →

Summary

The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.

Conditions

Interventions

DRUG

Nicotinamide Riboside

Capsule

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ChromaDex, Inc.

    collaborator INDUSTRY

  • Donna Hammond, PhD

    lead OTHER

Principal Investigators

  • Donna L Hammond, PhD · University of Iowa

  • Alexandra Thomas, MD · Wake Forest Baptist Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-08
Primary Completion
2021-08-18
Completion
2022-02-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642990 on ClinicalTrials.gov